# Progress Note 06 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Lorraine Hansberry (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML034-SYN
- Date: 2026-10-05
- Fictional facility: St. Posthumous Health Center
- Fictional author: Odette Marchetti-Fields, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Review six weeks after pancreaticoduodenectomy: pathology, diabetes, digestion, and the plan for chemotherapy after surgery. **S**

## History of present illness

Ms. Hansberry returns six weeks after a pylorus-preserving pancreaticoduodenectomy with resection of a segment of the superior mesenteric vein. She was in hospital nine days; her stomach was slow to empty for the first week and then recovered. Insulin glargine was started four days after surgery when her glucose rose, and her home fasting readings are now 140 to 170 mg/dL on 8 units. She finished four weeks of enoxaparin two weeks ago. Since surgery her stools have been loose and pale after larger meals despite pancrelipase. She has lost 2.4 kg since surgery. Pain is 2 out of 10 at the wound and she rarely needs oxycodone. She is writing again for an hour each morning. Fingertip tingling is barely there. She saw Dr. Adeyemi-Rourke last week, who recommends chemotherapy after surgery starting next week. She has had no thoughts of self-harm. **S**

| Element | Detail |
|---|---|
| Operation | Pylorus-preserving pancreaticoduodenectomy with vein resection; nine days in hospital; delayed gastric emptying resolved |
| Pathology | ypT2N1: 2.3 cm residual adenocarcinoma, 2 of 18 nodes, perineural invasion; all margins clear (R0); partial treatment response |
| Diabetes | Insulin glargine 8 units since day 4; fasting 140 to 170 mg/dL |
| Digestion | Loose, pale stools after larger meals; weight down 2.4 kg since surgery |
| Plan proposed | Six cycles of fluorouracil, leucovorin and irinotecan, without oxaliplatin, starting next week |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired in the afternoons; weight 51.8 kg; no fever |
| Gastrointestinal | Positive | Loose, pale stools after larger meals; eating five small meals; no vomiting |
| Endocrine | Positive | Fasting glucose 140 to 170 mg/dL; no low readings |
| Neurological | Negative | Fingertip tingling barely present |
| Cardiovascular | Negative | No leg swelling or calf pain |
| Psychiatric | Positive | Relieved about the margins, worried about the lymph nodes; PHQ-9 7, GAD-7 6; no thoughts of self-harm |

6 systems reviewed. **S**

## Current medications

- Pantoprazole 40 mg delayed-release oral tablet, one tablet by mouth once daily before breakfast **S**
- Oxycodone 5 mg oral tablet, one tablet by mouth every 4 hours as needed for pain **S**
- Senna 8.6 mg oral tablet, two tablets by mouth at night while taking oxycodone **S**
- Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nausea **S**
- Olanzapine 5 mg oral tablet, one tablet by mouth at night on days 1 to 4 of each cycle **S**
- Loperamide 2 mg oral capsule, two capsules at the first loose stool, then one after each loose stool, no more than eight a day unless directed **S**
- Insulin glargine 100 units/mL pen, 10 units under the skin at night **S**
- Pancrelipase delayed-release capsule (lipase 36,000 units), three capsules with each meal and two with each snack **S**

## Allergies

- No known allergy **S**

## Objective

BP 106/68 mmHg; pulse 86 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 99% on room air; weight 51.8 kg; BMI 19.5 kg/m². All vital signs are synthetic.

Hemoglobin: 10.6 g/dL (low); White cell count: 8.2 10*3/uL; Absolute neutrophil count: 5.1 10*3/uL; Platelets: 302 10*3/uL; Sodium: 137 mmol/L; Potassium: 4.3 mmol/L; Creatinine: 0.71 mg/dL; eGFR (CKD-EPI 2021): 116 mL/min/1.73 m²; Glucose: 156 mg/dL (high); ALT: 22 U/L; AST: 24 U/L; Alkaline phosphatase: 110 U/L (high); Total bilirubin: 0.5 mg/dL; Albumin: 3.4 g/dL (low); CA 19-9: 18 U/mL; PHQ-9: 7; GAD-7: 6; Pain score (0 to 10): 2; Urine albumin-to-creatinine ratio: 12 mg/g. All results are synthetic.

## Change since baseline

- Hemoglobin: 9.1 g/dL (low) at baseline, 10.6 g/dL (low) at this visit **S**
- White cell count: 7.4 10*3/uL at baseline, 8.2 10*3/uL at this visit **S**
- Platelets: 388 10*3/uL at baseline, 302 10*3/uL at this visit **S**
- Sodium: 138 mmol/L at baseline, 137 mmol/L at this visit **S**
- Potassium: 4 mmol/L at baseline, 4.3 mmol/L at this visit **S**
- Creatinine: 0.7 mg/dL at baseline, 0.71 mg/dL at this visit **S**
- eGFR (CKD-EPI 2021): 118 mL/min/1.73 m² at baseline, 116 mL/min/1.73 m² at this visit **S**
- Glucose: 132 mg/dL (high) at baseline, 156 mg/dL (high) at this visit **S**
- ALT: 48 U/L (high) at baseline, 22 U/L at this visit **S**
- AST: 41 U/L (high) at baseline, 24 U/L at this visit **S**
- Alkaline phosphatase: 236 U/L (high) at baseline, 110 U/L (high) at this visit **S**
- Total bilirubin: 1.6 mg/dL (high) at baseline, 0.5 mg/dL at this visit **S**
- Albumin: 3.6 g/dL at baseline, 3.4 g/dL (low) at this visit **S**
- Pain score (0 to 10): 5 at baseline, 2 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Thin, well; weight 51.8 kg; blood pressure 106/68, pulse 86 |
| Abdomen | Healed upper midline and right subcostal incision without hernia or redness; soft; mildly tender at the wound |
| Eyes | No icterus |
| Feet | Monofilament sensation and pulses normal; no lesions |
| Extremities | No leg swelling |
| Psychiatric | Engaged; planning her writing around the treatment days |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Pancreatic head adenocarcinoma, ypT2N1, R0 resection after modified FOLFIRINOX** (C25.0). A complete resection with clear margins after a partial response. Two lymph nodes were involved, so the risk of return is real. CA 19-9 is now normal at 18 U/mL. Dr. Adeyemi-Rourke recommends chemotherapy after surgery to complete about six months of treatment in all: six more cycles of fluorouracil, leucovorin and irinotecan every two weeks, keeping the reduced irinotecan dose and leaving out oxaliplatin so that the neuropathy does not return in her hands. She agrees. Counts, kidney and liver function allow it. **S**
   - Cycle 1 after surgery in one week, with pegfilgrastim on day 3.
   - Apixaban 2.5 mg twice daily again from the first cycle.
   - After chemotherapy: history, examination, CA 19-9 and CT every three to six months for two years.
2. **After pancreaticoduodenectomy** (Z90.411). Loose, pale stools after larger meals mean the enzyme dose is now too low after removal of the head of the pancreas; weight is 6.5 percent below the weight at diagnosis. **S**
   - Pancrelipase increased to three capsules (108,000 lipase units) with meals and two with snacks.
   - Dietitian review this week.
   - Vitamin D level at the next blood test.
3. **Diabetes due to pancreatic disease, now on insulin** (E08.9). Glucose 156 mg/dL today and fasting readings 140 to 170 on 8 units of glargine; no lows. Urine albumin-to-creatinine ratio 12 mg/g, normal. **S**
   - Insulin glargine increased to 10 units at night.
   - Hypoglycemia teaching repeated, with glucose tablets at her desk.
   - Dilated eye examination booked for next week.
   - A1c in December.
4. **Obstruction of the bile duct** (K83.1). Relieved: the stent was removed and the bile duct reconnected at surgery; bilirubin 0.5 mg/dL. **S**
   - Problem resolved.
5. **Oxaliplatin neuropathy, grade 1** (G62.0). Almost resolved; no oxaliplatin is planned. **S**
   - Review at each visit.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Surgical pathology | After resection | Up to date | ypT2N1 (2 of 18 nodes), R0, perineural invasion, CAP tumor regression score 2 |
| Laboratory | CA 19-9 | At diagnosis after biliary drainage, every two cycles during treatment, before surgery, after surgery, then every three to six months | Completed today | 18 U/mL, normal |
| Laboratory | Blood count with neutrophils and platelets | Before chemotherapy after surgery | Completed today | Hemoglobin 10.6 g/dL, white cells 8.2, neutrophils 5.1, platelets 302 |
| Laboratory | Kidney and liver function, electrolytes and albumin | Before chemotherapy after surgery | Completed today | Sodium 137, potassium 4.3 mmol/L; creatinine 0.71 mg/dL, eGFR 116; ALT 22, AST 24, alkaline phosphatase 110 U/L, bilirubin 0.5 mg/dL; albumin 3.4 g/dL |
| Imaging | Baseline CT after surgery | Before chemotherapy after surgery or within three months of surgery | Due | Ordered with the oncology team for before the third cycle after surgery; the CT before surgery showed no spread |
| Medication safety | Venous thromboembolism prophylaxis | After surgery and during chemotherapy | Completed today | Enoxaparin for four weeks after surgery completed; apixaban 2.5 mg twice daily to restart with chemotherapy |
| Self-management | Weight, nutrition and enzyme replacement | Each visit | Completed today | Weight 51.8 kg, 6.5 percent below the weight at diagnosis; pancrelipase increased; dietitian this week |
| Laboratory | Glucose and home readings | Each visit and before each cycle | Completed today | Glucose 156 mg/dL; home fasting 140 to 170 on 8 units of glargine |
| Laboratory | A1c | Every three months while treatment changes | Up to date | 7.0% eight weeks ago; next in December, three months after that one |
| Examination | Dilated eye examination and urine albumin-to-creatinine ratio | At diagnosis of diabetes, then yearly | Completed today | Urine albumin-to-creatinine ratio 12 mg/g today, normal, closing part of the deviation recorded at cycle 4. The dilated eye examination is booked for next week |
| Examination | Foot examination | At diagnosis of diabetes, then yearly | Completed today | Normal sensation and pulses |
| Examination | Oxaliplatin neuropathy: symptoms and examination | At each visit after oxaliplatin | Completed today | Almost resolved |
| Survey | Pain score and opioid review | Each visit | Completed today | Pain 2 out of 10 at the wound |
| Survey | Distress and depression screen (PHQ-9, GAD-7) | At diagnosis, at each treatment phase, and when symptoms change | Completed today | PHQ-9 7 and GAD-7 6 |
| Self-management | Serious illness conversation and advance care planning | At diagnosis and at each change in treatment | Completed today | Reviewed with palliative care last week; to be recorded formally at the preventive visit |

## Goal progress

- Endoscopy and pancreas-protocol CT within one week, tissue diagnosis and biliary drainage within two weeks, and a tumor board plan within three weeks of presentation. Outcome by 2026-05-04: Endoscopy in two days, CT in three, EUS biopsy and stent in one week, tumor board in nine days, consultation at two weeks. **S**
- Germline genetic testing with counseling and tumor molecular profiling resulted before surgery. Outcome by 2026-06-29: Germline panel negative; tumor KRAS G12D, microsatellite stable, no targetable alteration. **S**
- Six cycles of modified FOLFIRINOX before surgery with no delay of more than one week. Outcome by 2026-08-10: Six cycles; one dose reduction of irinotecan after diarrhea; CT shows a partial response. **S**
- Resection with clear margins if restaging shows no progression. Outcome by 2026-10-05: Pancreaticoduodenectomy with vein resection; margins clear (R0). **S**
- Pain 3 out of 10 or less with a clear head for writing. Outcome by 2026-06-29: Pain 1 to 2 out of 10 on oxycodone 5 mg once or twice a day. **S**
- Weight kept within 5 percent of the weight at diagnosis through chemotherapy, with enzyme replacement and dietitian support. Outcome by 2026-08-10: Weight 54.2 kg before surgery, 2 percent below the weight at diagnosis. **S**
- PHQ-9 below 10 throughout treatment, with support she chooses and palliative care alongside cancer treatment. Outcome by 2026-10-05: PHQ-9 between 6 and 8. **S**

## Medication changes

- Stopped: Pancrelipase delayed-release capsule (lipase 36,000 units), two capsules with each meal and one with each snack **S**
- Stopped: Insulin glargine 100 units/mL pen, 8 units under the skin at night **S**
- Started: Insulin glargine 100 units/mL pen, 10 units under the skin at night **S**
- Started: Pancrelipase delayed-release capsule (lipase 36,000 units), three capsules with each meal and two with each snack **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma (2026), National Comprehensive Cancer Network
- Khorana AA, et al. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2016;34(21):2541-2556 (PMID 27247221) (2016), American Society of Clinical Oncology
- Khorana AA, et al. Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update. J Clin Oncol 2019;37(23):2082-2088 (PMID 31180816) (2019), American Society of Clinical Oncology
- Sanders JJ, et al. Palliative Care for Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2024;42(19):2336-2357 (PMID 38748941) (2024), American Society of Clinical Oncology
- Key NS, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2023;41(16):3063-3071 (PMID 37075273) (2023), American Society of Clinical Oncology
- American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2026 (classification of diabetes, including diabetes of the exocrine pancreas) (2026), American Diabetes Association
- CMID: Clinical Monitoring Intelligence Database, diabetes mellitus (type 2) and anemia monographs (2026), Aether Forge
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force

## Follow-up

- Chemotherapy after surgery from next week. Dietitian and eye examination this week and next. Preventive visit in about two weeks. Call for fever of 38.0 °C or more, yellow eyes, low glucose readings, or worsening diarrhea. **S**
- Next scheduled visit 2026-10-21: periodic adult preventive visit during chemotherapy after surgery. **S**
